DermaTech Pty. Ltd.
http://www.dermatech.com.au
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From DermaTech Pty. Ltd.
Valeant Includes OTCs In Bid For Dramatic Growth By 2013
The Ontario-based firm has its sights set on becoming a top-15 pharma company with a $50 billion market capitalization by the end of 2013. Emerging markets and consumer health products, including the recent iNova and Fleming deals, play a big part in Valeant’s plans.
Valeant Includes OTCs In Bid For Dramatic Growth By 2013
The Ontario-based firm has its sights set on becoming a top-15 pharma company with a $50 billion market capitalization by the end of 2013. Emerging markets and consumer health products, including the recent iNova and Fleming deals, play a big part in Valeant’s plans.
Valeant Includes OTCs In Bid For Dramatic Growth By 2013
The Ontario-based firm has its sights set on becoming a top-15 pharma company with a $50 billion market capitalization by the end of 2013. Emerging markets and consumer health products, including the recent iNova and Fleming deals, play a big part in Valeant’s plans.
Valeant Includes OTCs In Bid For Dramatic Growth By 2013
The Ontario-based firm has its sights set on becoming a top-15 pharma company with a $50 billion market capitalization by the end of 2013. Emerging markets and consumer health products, including the recent iNova and Fleming deals, play a big part in Valeant’s plans.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- OTC, Consumer
-
Drug Delivery
- Topical Delivery
- Transdermal
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice